Clinical Trials Logo

Clinical Trial Summary

The goal of the study is to evaluate the effect of nutrition intervention on gastrointestinal symptoms, treatment discontinuation rate, nutritional parameters (e.g., dietary intake and eating habits), anthropometric measures, functional parameters, and QOL during the initiation and up-titration phase of incretin-based Anti Obesity Medications (AOM) treatment in patients with overweight/obesity. The nutrition intervention protocol will be developed based on literature review, focus groups with health care professionals, and patient interviews. A single-center pilot study will be performed at the Tel-Aviv Assuta Medical Center, among 10 patients who are about to initiate long-term weight management treatment with Wegovy© (semaglutide 2.4 mg), followed by a multi-center, parallel design open-label, RCT, which will be conducted at the Tel-Aviv Assuta Medical Center and Rabin Medical Center - Beilinson Hospital, in 120 patients who are about to initiate long-term weight management treatment with Wegovy©. The intervention group will receive nutrition guidance before AOM treatment by registered dietitian (RD) followed by nutrition and behavioral recommendations according to reported gastrointestinal symptom(s). The control group will receive the usual nutrition care for patients treated with AOM. Primary outcomes (gastrointestinal symptom assessment) and secondary outcomes (incretin-based AOM discontinuation rate, nutritional parameters, anthropometrics, functional parameters and QOL) will be evaluated by interviews, questionnaires and measurements at baseline, at the end of Wegovy© titration phase [20 weeks (T1)] and weekly during the study period (for GI symptoms assessment).


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT06431308
Study type Interventional
Source Ariel University
Contact Shiri Sherf-dagan, Ph.D
Phone +972747288004
Email shiris@ariel.ac.il
Status Not yet recruiting
Phase N/A
Start date June 1, 2024
Completion date April 30, 2026

See also
  Status Clinical Trial Phase
Enrolling by invitation NCT05162001 - Body Weight Response With Disulfiram in Humans Early Phase 1
Completed NCT03141476 - Adequacy of Perioperative Cefuroxime Dosage According to the BMI Phase 4
Recruiting NCT05176626 - Long-term Effectiveness of the Antiobesity Medication Phentermine Phase 4
Completed NCT04730375 - Evaluation of the Effect of Different Doses Dexmedetomidine Infusion on Lung Mechanics and Oxygenation in Obese Patients Phase 2
Recruiting NCT03593668 - Effect and Safety of Benaglutide or Metformin in Patients With Simple Obesity Who Have Inadequate Weight Control Phase 4
Recruiting NCT05087342 - Latino Semaglutide Study Phase 3
Recruiting NCT06390501 - The Effect of Weekly Semaglutide Treatment on Energy Expenditure N/A